<DOC>
	<DOCNO>NCT01039363</DOCNO>
	<brief_summary>The prognosis elderly patient relapse refractory acute myeloid leukemia ( AML ) grave . Because chronological age and/or presence multiple co-morbidities , treatment-related mortality elderly patient AML quite high although high intensive treatment mandatory overcome chemoresistant characteristic disease . Several regimen evaluate salvage chemotherapy relapse refractory AML Mitoxantrone/High dose Cytarabine Amsacrine/High dose Cytarabine . These regimen could achieve complete remission ( CR ) part patient , result higher treatment relate mortality ( TRM ) . Accordingly , less intensive salvage regimen need elderly patient relapse refractory AML . The activity histone deacetylase ( HDAC ) inhibitor , Vorinostat Suberoylanilide hydroxamic acid ( SAHA ) , AML suggest cell line model animal model well phase 1 trial . The phase 1 study determine MTD oral Vorinostat 200mg twice daily 250mg thrice daily . In addition , phase 1 trial show antitumor activity Vorinostat 17 % response rate patient advance leukemia myelodysplastic syndrome ( MDS ) . Accordingly , study recommend demonstrate clinical activity Vorinostat AML . In term combine drug Vorinostat , anthracycline one best candidate . A vitro study demonstrate combination anthracycline ( esp . idarubicin ) HDAC inhibitor significant clinical activity leukemia . Another candidate Gemtuzumab ozogamicin , calicheamicin-conjugated antibody direct CD33 antigen AML blast . The U.S. FDA also approve use GO relapse AML monotherapy . A study also show combinational therapy GO attenuate dos standard induction chemotherapy could successfully induce CR without increase treatment-related mortality AML patient age 55 older . A vitro study report HDAC inhibitor valproic acid augment clinical activity GO toward CD33+ AML cell . The study demonstrate strategy use HDAC inhibitor together GO could potentially induce synergistic proapoptotic activity AML blast without increase toxicity . In center , far treat relapsed refractory AML patient use salvage regimen include GO ( 3mg/m2/dayx1day ) plus attenuated Idarubicin/Cytarabine ( Idarubicin 12mg/m2/day 2 day intermediate dose Cytarabine ) . So far , CR rate regimen around 50 % without increase TRM . Accordingly , determine efficacy toxicity Vorinostat-incorporating salvage regimen base GO+IA chemotherapy patient 50 year old old relapse refractory AML .</brief_summary>
	<brief_title>Vorinostat Combined With Gemtuzumab Ozogamicin , Idarubicin Cytarabine Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Age &gt; 50 year . 2 . ECOG Performance Status 0 , 1 2 3 . Life expectancy least 12 week . 4 . Subjects relapse refractory kind chemotherapy acute myeloid leukemia express CD33 antigen â‰¥ 50 % myeloblast . 5 . Adequate liver renal function assess follow laboratory requirement conduct within 7 day adequate bone marrow within 14 day prior screen : 1 . Total bilirubin &lt; 1.5 time upper limit normal 2 . ALT AST &lt; 2.5 x upper limit normal 3 . Alkaline phosphatase &lt; 4 x ULN 6 . PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] 7 . Serum creatinine &lt; 1.5 x upper limit normal . 8 . Signed date informed consent start specific protocol procedure . 1 . History cardiac disease : congestive heart failure &gt; NYHA class 3 4 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrythmias require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 2 . History HIV infection chronic hepatitis B C ( except case receive Lamivudine entecavir control HBV infection ) 3 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) 4 . Patients seizure disorder require medication ( antiepileptic ) 5 . Patients evidence history bleed diasthesis diagnosis acute myeloid leukemia 6 . Patients undergoing renal dialysis 7 . Anticancer chemotherapy immunotherapy study within 4 week study entry . 8 . Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow ) . Major surgery within 4 week start study 9 . Investigational drug therapy outside trial within 4 week study entry 10 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 11 . Any condition unstable could jeopardize safety patient compliance study , Alzheimer 's disease dementia 12 . Patients unable swallow oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Relapse refractory acute myeloid leukemia</keyword>
</DOC>